Articles from Applied DNA Sciences, Inc.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company focused on providing nucleic acid production solutions, today announced up to $58 million in commitments for a private investment in public equity (“PIPE”) offering led by institutional investors to initiate a digital asset treasury strategy based on BNB, the native cryptocurrency of the Binance blockchain ecosystem, the world’s largest cryptocurrency exchange1. Following the closing, the Company intends to begin deploying funds to acquire BNB, creating a gateway for institutional and retail investors to participate in the BNB blockchain and Binance ecosystem that powers millions of users and decentralized applications worldwide.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release financial results for the three months ended March 31, 2023 after the market close on Thursday, May 11, 2023. The Company will host a conference call for the investment community to discuss the results and answer questions at 4:30 p.m. ET.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the "Company"), a leader in PCR-based DNA technologies, announced that its CertainT® supply chain traceability platform is featured in an article on the home page of the New York Times website today. The article, titled "How A.I. and DNA Are Unlocking the Mysteries of Global Supply Chains," centers on the mounting need for the textile and other industries to employ tracing technologies to ensure compliance with the Uyghur Forced Labor Prevention Act (UFLPA).

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it has established a new high bar for the production of DNA with the manufacture and shipment of a multi-gram quantity of linearDNA™ in under six weeks. The quantity was produced by the Company’s LinearDNA™ platform under a large recurring purchase order with a global manufacturer of in vitro diagnostics that was announced in the first quarter of fiscal 2023 and is the largest single shipment of linearDNA to date. The Company expects to ship a final multi-gram quantity in the third fiscal quarter of 2023 to fulfill the purchase order earlier than contractually stipulated.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a validation package to the New York State Department of Health (NYSDOH) in support of approval for a pharmacogenomics (PGx) assay as a NYSDOH laboratory-developed test (LDT). If approved by NYSDOH, the LDT test will be used by ADCL to power its population-scale PGx testing services.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the receipt of an up to $1.5 million award from New York State’s Empire State Development (ESD) agency. The award is provided by ESD under the Excelsior Jobs Program for qualifying net new job creation as refundable employee tax credits claimed over a benefit period of up to 10 years. It will be used by Applied DNA to support the ongoing development and establishment of the enzymatic production of cGMP linearDNA™ for use in the manufacture of genetic medicines.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the first quarter of fiscal 2023, ended December 31, 2022.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that it will release financial results for the three months ended December 31, 2022, after the market closes on Thursday, February 9, 2023. The Company will host a conference call for the investment community to discuss its results and answer questions at 4:30 p.m. ET.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced the publication of a peer-reviewed research article in Molecular Therapy – Methods & Clinical Development. The study, titled ‘A linear DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain elicits protective immunity in domestic cats,’ supports the further development of the Company’s LinearDNA™ platform for the large-scale enzymatic (PCR, polymerase chain reaction) production of prophylactic and therapeutic linearDNA™-based vaccines. An initial manuscript detailing the study’s findings was published in preprint form on bioRxiv in July 2022.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the fourth quarter and fiscal year ended September 30, 2022.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, announced today plans to establish a new, separate manufacturing facility to be located in Suffolk County, New York, for the enzymatic production of cGMP LinearDNA™ for use in genetic medicines. The expansion plan will double the Company's production capacity and is being undertaken in response to the growing number of new nucleic acid-based therapies under development1 and in the market that are driving greater demand for high-quality, large-scale therapeutic DNA, as well as a healthy backlog of repeat and new proof-of-concept orders, the latter from leading pharma/biotech customers that have expressed a long-term need for cGMP DNA at scale. Concurrently, the Company is in active discussions with New York State, local municipalities, and private entities regarding funding opportunities that may assist in underwriting the costs of its planned cGMP build-out.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, announced today that it received its largest single purchase order for LinearDNA™ valued above the mid-six-figures. The order was placed under a long-standing supply agreement for the bulk manufacture of LinearDNA for a global manufacturer of in vitro diagnostics. Under the terms of the repeat order, the Company will deliver quantities of LinearDNA to the customer in the current quarter, with the full order expected to be fulfilled over the subsequent three quarters.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain reaction (PCR”)-based technologies, today announced the publication of a manuscript, co-authored with international academic and industry scientists, containing data demonstrating that a LinearDNA™-based vaccine candidate (the “vaccine candidate”) reduced infectious virus shedding and was protective against SARS-CoV-2 in a challenge trial in ferrets. The purpose of the challenge trial was to demonstrate that LinearDNA-based vaccines can express therapeutic antigens that can confer protection against infection.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (‘Applied DNA’ or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, and the Cornell University College of Veterinary Medicine (“CUCVM”) announced the signing of a research agreement (the “Agreement”) to advance LinearDNA™-based vaccine research and discovery for animal diseases with agricultural biosecurity implications. Primarily, the Agreement seeks to combine LinearDNA as a platform for rapid drug development with CUCVM’s expertise in viral vector design to advance a differentiated approach to animal vaccine development for infectious diseases.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 2:00 pm Eastern Time. The conference is being held as a hybrid in-person/virtual event from September 12 to 14, 2022.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), has launched monkeypox testing as a clinical reference laboratory testing service available to hospital systems and clinical labs located in New York State and in states that recognize New York's CLEP/CLIA certification for testing.

Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC ("ADCL"), has submitted to the New York State Department of Health (NYSDOH) a validation package for its Company-developed monkeypox virus test in support of a request for full approval as a form of NYSDOH Laboratory Developed Test (LDT). The PCR-based diagnostic is designed to identify the genetic signature of the Clade II variant of the monkeypox virus that is currently prevalent in the U.S. If approved by NYSDOH, the test will be used to power ADCL's monkeypox testing services.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in PCR-based DNA technologies, today announced consolidated financial results for the third quarter of fiscal 2022, ended June 30, 2022. The Company’s results are in line with preliminary selected quarterly results issued in the Company’s Form S-1/A filed on August 1, 2022.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that LineaRx, the Company’s majority-owned biotherapeutics subsidiary, has for the first time successfully administered and expressed a linearDNA-LNP construct in mice via routine intramuscular (IM) injection without the concurrent use of electroporation (EP) that utilizes electrical pulses to deliver DNA to target cells. The Company believes that the removal of the concurrent use of EP during administration potentially increases the commercial viability of LinearDNA-based therapies.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, today announced that The City University of New York (CUNY), the largest urban university in the United States, has extended its health services contract for COVID-19 testing and vaccine policy management with the Company’s wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), for 12 months through July 2023 and at the prior contract terms. ADCL’s COVID-19 testing volumes, including the CUNY contract, fueled the Company’s record fiscal 2021 revenues and consecutive quarterly record revenues in the first half of fiscal 2022 ended March 31, 2022.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that Dr. James A. Hayward, president and CEO, and Beth Jantzen, chief financial officer, will host a conference call and webcast on Thursday, August 11, 2022, at 4:30 p.m. ET to provide financial results and corporate updates for the fiscal third quarter of 2022.

Applied DNA Sciences, Inc., (NASDAQ: APDN) (the “Company” or “Applied DNA”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced the closing of its previously announced public offering of 3,000,000 shares of its common stock (or common stock equivalents in lieu thereof), together with Series A warrants to purchase up to 3,000,000 shares of its common stock and Series B warrants to purchase up to 3,000,000 shares of its common stock at a combined offering price to the public of $4.00 per share (or common stock equivalent) and associated warrants, priced at a premium to market under Nasdaq rules. The gross proceeds to the Company from the offering were $12 million before deducting the placement agent’s fees and other offering expenses payable by the Company.

Applied DNA Sciences, Inc., (NASDAQ: APDN) (the “Company” or “Applied DNA”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced the pricing of a public offering of 3,000,000 shares of its common stock (or common stock equivalents in lieu thereof), together with Series A warrants to purchase up to 3,000,000 shares of its common stock and Series B warrants to purchase up to 3,000,000 shares of its common stock at a combined offering price to the public of $4.00 per share (or common stock equivalent) and associated warrants, priced at a premium to market under Nasdaq rules. The Series A warrants will have an exercise price of $4.00 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. The Series B warrants will have an exercise price of $4.00 per share, are exercisable immediately upon issuance, and will expire thirteen months following the date of issuance. The closing of the offering is expected to occur on or about August 8, 2022, subject to the satisfaction of customary closing conditions.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), has initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus. The test has been developed as a type of NYSDOH Laboratory Developed Test (“LDT”). If the test is validated by ADCL, a validation package will be submitted to New York State Department of Health (“NYSDOH”) for approval. If approved, the test will be used to power ADCL’s monkeypox testing services.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, today announced the publication of a manuscript containing data demonstrating that a linearDNA vaccine successfully elicited neutralizing antibodies and cellular immunity against SARS-CoV-2. The manuscript, authored by LineaRx, the Company’s majority-owned biotherapeutics subsidiary, and LineaRx’s development partner, EvviVax, S.R.L., further establishes the utility of the LinearDNA ("linDNA) platform as a large-scale enzymatic production approach to prophylactic and therapeutic veterinary vaccine applications.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based technologies, today announced that Dr. James A. Hayward, president and CEO of Applied DNA and its majority-owned biotherapeutics subsidiary, LineaRx Inc., will present data highlighting the advantages of its enzymatically produced linearDNA (linDNA) as an IVT template for mRNA production at the 2nd Annual mRNA-Based Therapeutics Summit on July 26-28, 2022, in Boston, Massachusetts.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, announced the formal launch of business development initiatives to expand the biotherapeutics industry’s awareness of the LinearDNA™ platform (the “platform”) as an alternative to current plasmid-based (pDNA) production processes used in the manufacture of DNA for advanced nucleic acid-based therapies. The initiatives, undertaken by LineaRx, Inc., a Company subsidiary focused on the commercialization of enzymatically produced DNA, position the platform as a source of high-fidelity DNA to help empower the rapid growth of advanced nucleic acid-based therapies. The initiatives include pre-print and peer-reviewed publications of upcoming preclinical data reads, presentations at industry conferences, business development activities related to partnering opportunities, and a revamp of the LineaRx website.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, has been increasing its engagement with all stakeholders in anticipation of the June 21, 2022, effective date of the “rebuttable presumption” standard under the Uyghur Forced Labor Prevention Act (UFLPA) signed into law on December 23, 2021. Under the UFLPA, all imports that originate from China's Xinjiang Uyghur Autonomous Region (XUAR) or otherwise use Uyghur or other minorities for forced labor in China, are excluded from entry into the U.S. by the Customs and Border Protection agency (CBP) of the Department of Homeland Security (DHS).

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, and its program development partner, EvviVax, S.R.L. ("EvviVax"), today announced the peer-reviewed publication of preclinical animal data in The Journal of Experimental & Clinical Cancer Research that supports the use of Applied DNA’s LinearDNA™ platform to produce veterinary DNA cancer vaccines. LinearDNA is Applied DNA's proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale, cell-free production of high-fidelity DNA sequences.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in cell-free, enzymatic DNA production, today announced consolidated financial results for the second quarter of fiscal 2022, ended March 31, 2022.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events’ sub-page of the Company’s Investor Relations website and embedded into the live webcast.

Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in cell-free, enzymatic DNA production, today announced that CEO Dr. James A. Hayward is invited to present at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT. Dr. Hayward’s presentation will be available on-demand for the duration of the conference via the sign-up link: Sign up here to access the presentation

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today the closing of its previously announced registered direct offering with an institutional investor of 1,496,400 shares of common stock (or common stock equivalents) at a price of $2.80 per share for gross proceeds of approximately $4.2 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. In a concurrent private placement, Applied DNA also issued to the institutional investor in the offering unregistered warrants to purchase up to an aggregate of 1,496,400 shares of common stock.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1,496,400 shares of common stock (or common stock equivalents) at a price of $2.80 per share, in a registered direct offering, resulting in total gross proceeds of approximately $4.2 million, before deducting the placement agent’s fees and other estimated offering expenses. The Company has also agreed to issue to the investor unregistered warrants to purchase up to an aggregate of 1,496,400 shares of common stock in a concurrent private placement. The warrants will have an exercise price of $2.84 per share, be exercisable six months from the date of issuance and will expire five years from the initial exercise date.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, and its program development partner, EvviVax, S.R.L. ("Evvivax"), today announced the publication of a manuscript detailing a preclinical study (the “study”) showing that LinearDNA™ vaccines used for cancer immunotherapy produced a strong immune and specific antitumoral response in preclinical mouse models. The study investigated the use of the LinearDNA platform to produce DNA vaccines targeting either tumor-associated antigens (TAA) or tumor-specific antigens (TSA or tumor neoantigens). The manuscript, “Linear DNA Amplicons as a Novel Cancer Vaccine Strategy,” is published online on the bioRxiv.org preprint server and has been submitted for peer-reviewed publication. LinearDNA is Applied DNA’s proprietary, large-scale polymerase chain reaction ("PCR")-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the first quarter of fiscal 2022, ended December 31, 2021.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2022 first quarter financial results after market close on Thursday, February 10, 2022. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events’ sub-page of the Company’s Investor Relations website and embedded into the live webcast.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), intends to deploy its Linea™ 1.0 COVID-19 Assay (the “Linea 1.0 Assay” or the “Assay”), part of ADCL’s Linea COVID-19 diagnostics and testing portfolio, for the rapid detection of samples containing a mutation profile that is indicative of the BA.2 subvariant (BA.2) of Omicron in COVID-19-positive samples.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) for its Linea™ 2.0 COVID-19 Assay (the “Linea 2.0 Assay”) and Linea™ Unsupervised At-Home Sample Collection Kit (the “Linea Collection Kit”).

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has seen COVID-19 testing levels increase greater than 90% (unaudited) for the quarter ended December 31, 2021, compared to the fiscal quarter ended September 30, 2021. ADCL has also seen a further strengthening of demand since the quarter ended December 31, 2021, to date. ADCL attributes the increase in demand to current safeCircle™ clients seeking to safely reopen or increase activities at municipalities, campuses, and businesses and the on-boarding of new clients. ADCL’s safeCircle program is a fully integrated testing platform for enterprise and educational institutions that provides a full range of COVID-19 diagnostic testing and associated services, including sample collection, test site infrastructure design and management, results tracking, and vaccination status management.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs (ADCL), has received conditional approval from the New York State Department of Health (NYSDOH) for its Linea™ 2.0 Assay (the “Linea 2.0 Assay”) as a Laboratory Developed Test (LDT), pending a final review of the assay’s validation data by NYSDOH. With the conditional approval, ADCL can immediately employ the Linea 2.0 Assay for COVID-19 testing to support New York State-based safeCircle™ clients for the diagnostic testing of COVID-19. The Linea 2.0 Assay is conditionally approved for individual and pooled (up to 5-samples) testing.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, and Stratum Reservoir (Isotech), LLC (“Isotech”), a division of Stratum Reservoir and a leader in laboratory stable isotope analysis, a technique used for fingerprinting naturally occurring organic compounds such as cotton, today announced that they have entered into a Memorandum of Understanding (MoU). Under the terms of the MoU, Applied DNA will deploy Isotech’s isotopic analysis (IA) as a confirmatory assay for cotton genotyping, the process through which cotton DNA is utilized to determine cotton fiber and fabric origin forensically. The MoU is expected to be followed by a definitive agreement between the companies.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the full fiscal year and quarter ended September 30, 2021.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced today a development in its cotton genomics program (the “Program”) that the Company believes can bring forensic proof of cotton authenticity and provenance specifically related to regional cotton varietals to give brands and relevant regulatory authorities access to fiber origin data regardless of location of manufacture. The Company recently presented initial data describing a methodology and findings for the successful determination of Egyptian cotton fiber, yarn and fabric origin using the combination of cotton genomics and isotopic analysis (IA) at an American Apparel and Footwear Association event. Applied DNA intends to publish its methodology and data upon completion of its manuscript.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report its fourth quarter and full fiscal year 2021 financial results after market close on Thursday, December 9, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘Company Events’ sub-page of the Company’s Investor Relations website and embedded into the live webcast.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced its COVID-19 diagnostic strategy in response to the emergence of Omicron (B.1.1.529), a newly identified SARS-CoV-2 variant of concern. The Company plans to introduce its Linea™ 2.0 COVID-19 Assay (“Linea 2.0”), a new RT-PCR assay for the SARS-CoV-2 E and N genes that builds on the Company’s established COVID-19 line of diagnostics, after submission of its validation data to the New York State Department of Health (NYSDOH) in the next few days.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, and its majority-owned subsidiary LineaRx, Inc., a manufacturer of LinearDNA™ via PCR for nucleic acid therapeutics and diagnostics, today announced the receipt of repeat orders from diagnostic customers and a first Contract Research Organization (CRO) order from a new biotherapeutic customer, a federally funded research and development laboratory focused on cancer research. PCR-produced LinearDNA serves as a pure, fast, and flexible alternative to plasmid DNA (pDNA) in the manufacture of cell and gene therapies (CGTs) and nucleic acid vaccines. CRO orders typically provide a means to evaluate LinearDNA within a customer’s preclinical development program.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced the publication of a study in Molecular Therapy: Methods and Clinical Development on a methodology for the manufacture of novel types of CAR constructs that employ the Company’s LinearDNA™ as part of a manufacturing process for the efficient generation of CD19-specific CAR T-cells (CAR19 T-cells) based on co-electroporation of a LinearDNA transposon and mRNA encoding of piggyBac transposase. PCR-produced LinearDNA is manufactured by LineaRx, the Company’s majority-owned subsidiary, to serve as a pure, fast, and flexible alternative to plasmid DNA (pDNA) for biotherapeutic applications.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced that it has submitted its request for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) for its Linea™ SARS-CoV-2 Mutation Panel (the “Mutation Panel”). The Mutation Panel is designed for the qualitative detection of the E484K, E484Q, L452R, and N501Y SARS-CoV-2 genetic mutations in samples that have tested positive for COVID-19 on the Company’s EUA authorized Linea™ COVID-19 Assay Kit. The E484K, L452R, and N501Y mutations have been identified by the Centers for Disease Control and Prevention (“CDC”) as potentially having a negative impact on the efficacy of certain anti-SARS-CoV-2 monoclonal antibody treatments (“mAb”) and have been identified by the CDC as substitutions of therapeutic concern.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies including diagnostics, and CLEARED4, one of the nation’s largest and most trusted health verification platforms, stand ready to help large employers prepare for compliance with the federally directed OSHA Emergency Temporary Standard (“ETS”) with a turnkey and cost-effective integrated offering to efficiently track employee COVID-19 vaccination status and the provision of fast and accurate weekly pooled COVID-19 testing using the Company’s RT-PCR test. Under the ETS, large employers (100+ employees) have until January 4, 2022, to ensure that their workforce is fully vaccinated or require any workers who remain unvaccinated to produce a negative test result on at least a weekly basis before coming to work.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced signing a mutual collaboration agreement (the “Agreement”) with Ganesha Ecosphere Ltd. (BSE: GANECOS) (Ganesha), the largest recycled polyester (rPET) fiber producer in India with over 300-plus customers, 250-plus suppliers, and 500-plus product variants. Under the terms of the Agreement, Ganesha will deploy the CertainT® platform, Applied DNA’s traceability system, to tag an initial pilot production of recycled polyester (rPET) at Ganesha’s facilities in India and conduct confirmatory samples testing at Applied DNA’s laboratories in India and the U.S. The collaboration between the two companies will provide brands and textile manufacturers with a trusted solution to support their sustainability goals for rPET and confirm raw material authenticity at all stages of the textile value chain.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, announced that safeCircle™, its high-throughput, pooled COVID-19 testing program, has been implemented at Sarah Lawrence College (the “College”) as an addition to the College’s in-house testing practice to monitor for the prevalence of COVID-19 during the College’s Fall 2021 semester. Testing began this week and is available to asymptomatic students, faculty, and staff on a voluntary basis. The College’s population of approximately 2,000 undergraduate and graduate students, faculty, and staff are required to be vaccinated against COVID-19.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that it received purchase orders from a textile customer totaling $1.6 million to supply molecular taggant to tag textile fibers. The Company expects to ship the majority of the total value of the purchase orders during the current quarter ending September 30, 2021, with the balance expected to be shipped in the subsequent quarter.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that its CertainT® platform has added support for StrainSecure 2.0 by TruTrace Technologies, Inc. (CSE: TTT; OTCQB: TTTSF) (“TruTrace”) that builds on the companies’ strategic sales, marketing, and technology integration partnership to advance their vision of an integrated, cannabis product validation and authentication supply chain security solution for cannabis companies. The two companies recently announced that Flora Growth (“Flora”) will utilize their integrated solution be as part of Flora’s global cannabis product validation platform. TruTrace is the developer of a fully integrated blockchain platform for the legal cannabis, food, and pharmaceutical industries.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that it has entered into a Master Services Agreement (the “MSA”) with Flora Growth (NASDAQ: FLGC) (Flora) to deploy the Company’s CertainT® platform as part of Flora’s global cannabis product validation and authentication platform for consumers, distributors, and government regulators. Concurrently, the Company received a Statement of Work (SOW) under the MSA from Flora to implement its CertainT platform and supply related equipment and services for three locations (1 in Florida; 2 in the Republic of Colombia), where the Company’s molecular tags will be applied to quantities of Flora’s cannabis flower and derivatives, as well as select products in their portfolio. Financial terms of the SOW were not disclosed.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that Dr. James A. Hayward, president and CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference to be held virtually from September 13 – 15, 2021.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC, (ADCL) was awarded a testing contract by Suffolk County Community College (the “College”) to monitor for the prevalence of COVID-19 among its unvaccinated staff and faculty in support of the College’s reopening in the fall (the “Contract”). Testing is scheduled to begin in the second half of September 2021. The College, part of the State University of New York (SUNY) system, is aligned with SUNY’s vaccination mandate, which requires all on-campus students to be fully vaccinated against COVID-19 by September 27, 2021.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the three and nine months ended June 30, 2021.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2021 third quarter financial results after market close on Thursday, August 12, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. EDT that same day. Presentation slides will also be posted to the ‘IR Calendar and Corporate Presentations’ sub-page of the Company’s corporate website and embedded into the live webcast.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing and nucleic acid-based technologies, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC, (ADCL) was awarded a competitively-bid COVID-19 testing contract by the City University of New York (CUNY) Board of Trustees to facilitate the University’s reopening in the fall (the “Contract”). The Contract term is 12 months, has a maximum value not to exceed $35.0 million, and contains no minimum weekly testing commitment.

Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and American & Efird, (A&E), the world’s foremost thread manufacturer, today announced A&E’s INTEGRITY™ advanced identification thread technology is available for its ECO100 recycled sewing thread line. Utilizing Applied DNA Sciences’ CertainT® molecular-based technology, A&E’s introduction of INTEGRITY™ ECO100, a sustainable and secure thread, provides an innovative and economical solution for brands to authenticate and validate their products anywhere within the supply chain by way of a common component – sewing thread.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today announced results from an in vitro neutralization study of sera from the trial cohort comprised of 11 domestic felines vaccinated with the Applied DNA-Evvivax LinearDNA™ COVID-19 vaccine candidate against the B.1.1.7 (U.K.), P1 (Brazil), and B.1.526 (New York) SARS-CoV-2 variants. This study extends the previously announced induction by the vaccine candidate of neutralizing antibodies against functional virus of the D614G lineage and showed that all 11 vaccinated felines produced neutralizing antibody titers against all three variants.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its wholly-owned subsidiary, Applied DNA Clinical Labs, LLC (ADCL), has secured a safeCircle™ pooled COVID-19 surveillance testing contract with Camp Chateaugay, an overnight summer camp program for teens and kids based in New York’s Adirondack Mountain region. The acquisition of safeCircle’s newest client reflects the service’s focus on profitable niche markets for COVID-19 testing and the re-opening of venues for sales opportunities in which routine COVID-19 pooled surveillance testing would lower the risk of virus spread as vaccinated and under-vaccinated populations come into close contact.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it has competed technical validation of all seven Research Use Only (RUO) mutation detection assays contained in its Linea™ COVID-19 Selective Genomic Surveillance™ (SGS) Mutation Panel (the “SGS Panel”) across 125 COVID-19 positive clinical samples known to include COVID-19 variants. The results showed 100% concordance when compared to the results of Whole Genome Sequencing (WGS) of the same samples (see table below for a listing of all mutation detection assays and currently associated Variants of Concern (VoC) or Variants of Interest (VoI)). The SGS Panel can be run in hours and can utilize the same extracted viral RNA that was used to obtain the original COVID-19 diagnosis. The SGS Panel will be available on a RUO basis and cannot be used for diagnostic purposes. Based on its successful technical validation, the Company plans to seek EUA-authorization for its SGS Panel.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), today clarifies the scope of its newly authorized asymptomatic serial screening indication for its Linea COVID-19 Assay Kit (the “Assay Kit”) and certain information contained in its previously disseminated 12 May 2021 press release (the “Press Release”) relating to the U.S. Food and Drug Administration’s (FDA) grant of a re-issued Emergency Use Authorization (EUA) that expands the Assay Kit for asymptomatic serial screening testing.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced consolidated financial results for the three and six months ended March 31, 2021.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company’s Linea™ COVID-19 Assay Kit (the “Assay Kit”) a re-issued Emergency Use Authorization (EUA) that expands the Assay Kit’s intended use to include serial screening of asymptomatic individuals. The expanded intended use allows for the serial testing of individuals with or without symptoms, eliminates the prescription requirement, and returns results to individuals. With the recent receipt of CLIA certification by its Applied DNA Clinical Labs, LLC (ADCL) subsidiary, the expanded intended use enables the Company to now offer recurring testing strategies with individual result reporting without a prescription to support the safer reopening of schools, workplaces, nursing homes and skilled nursing facilities, and other places where people gather regularly in numbers. The Assay Kit with its expanded intended use is also available for immediate purchase by CLIA-certified laboratories nationally.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that its Applied DNA Clinical Labs, LLC (ADCL) subsidiary received CLIA (Clinical Laboratory Improvement Amendments) certification from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for COVID-19 testing using EUA-authorized methods and devices. With this certification, ADCL can now serve as a diagnostic laboratory to conduct high throughput diagnostic COVID-19 testing utilizing EUA-authorized testing platforms, including the Company’s Linea™ COVID-19 Assay Kit. ADCL’s CLIA certification umbrella includes its Limited Service Laboratory (LSL) certification for Point-of-Care testing using COVID-19 molecular and antigen assays and community screening applications for COVID-19 and influenza.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it will report fiscal 2021 second quarter financial results after market close on Thursday, May 13, 2021. The Company’s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will also be posted to the ‘IR Calendar’ section of the Company’s corporate website and embedded into the live webcast.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and its program development partner, Evvivax, S.R.L. (“Evvivax”), today announced a booster injection delivered 30 days after the prime vaccination elicited an average boost in SARS-CoV-2 neutralizing antibody (NAb) levels (titers) by over 5-fold, with every member of the trial cohort producing NAbs. The antibodies produced by the members of the feline cohort were tested against functional SARS-CoV-2 virus of the D614G lineage. The D614G mutation is present in most variants. Testing showed that neutralizing titers were detected in feline sera with a geometric mean titer for the cohort of 398. The average NAb titer results post-booster exceeded the three- to four-fold enhancement previously predicted by the Company. The Company expects to have cellular immunity data for the feline cohort in the coming weeks.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced it has entered into a new contract with the Defense Logistics Agency’s (DLA) Land and Maritime’s Product Test Center (PTC) in Columbus, Ohio. The firm fixed-price, indefinite delivery contract (IDC) provides for a maximal contract value to the Company of $1.04 million over an up to five-year performance term. Applied DNA was awarded the original contract in 2014, with the primary objective of supporting the DLA’s counterfeit mitigation initiatives, and product verification and testing programs specific to FSC 5962 microcircuits. The newly awarded contract outlines the Company’s provision of supplies and services, including creation of unique DNA marks in various inks, QC authentication testing and training.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that it secured an amendment to a Master Services Agreement (MSA) with an existing customer of its Linea™ COVID-19 Assay Kit (the “Assay Kit”). The amendment doubles the undisclosed maximal value of the MSA to ensure the customer’s continuing access to the Assay Kit for the customer’s pooled COVID-19 surveillance testing program. Concurrently, the Company announced the receipt of a purchase order for its Assay Kits and consumables to enable the customer to conduct 16,000 tests to be used for recurring surveillance testing and support the customer’s in-person graduation ceremonies in May 2021.

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today provided a preliminary estimated revenue range for the fiscal second quarter ended March 31, 2021 and a business update. The Company expects revenues for its fiscal second quarter to be in the range of $2.5 million to $2.7 million. This compares to revenues of $1.6 million in the fiscal first quarter of 2021 and $552 thousand in the fiscal second quarter of 2020. The sequential growth in quarterly revenues was driven principally by demand for safeCircle™, the Company’s pooled COVID-19 surveillance testing program, and from sales of its Linea™ COVID-19 Assay Kit (the “Assay Kit”).

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced an interview with President and CEO Dr. James A. Hayward conducted by the BBC’s Business Daily as part of an episode titled ‘Tracing cotton’s DNA’. The episode is available at https://www.bbc.co.uk/sounds/play/w3ct1jn9.